Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
A phase 3 trial of Durvalumab, Tremelimumab, Carboplatin, Gemcitabine + cisplatin, Gemcitabine and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) is a phase 3 interventional study registered as NCT02542293 by AstraZeneca, with 953 participants enrolled, started 2015-11-03 and due to reach its primary completion in 2020-09-21. Interventions recorded: Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin and Pemetrexed + carboplatin. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialPhase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Shares Gemcitabine + cisplatin, Tremelimumab, Durvalumab, Gemcitabine and the tag pipeline.
- TrialStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.
- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Tremelimumab, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.
- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Tremelimumab, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.
- TrialDurvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.
- TrialA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Shares Tremelimumab, Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialAK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Durvalumab, Cisplatin, AstraZeneca, Carboplatin and the tag pipeline.